Please enter exact key words
A Novel Anti-TSHR Monoclonal Antibody

for the Treatment of Thyroid Diseases

Home / Available Projects / A Novel Anti-TSHR Monoclonal Antibody
Drug Name GPCR-targeted Project 001

A monoclonal antibody that acts as a thyroid stimulating hormone receptor (TSHR) antagonist is in early clinical development for the treatment of patients with Graves’ disease or thyroid cancer. Grave’s disease is an autoimmune disease that leads to a generalized overactivity of the entire thyroid gland (hyperthyroidism).

Target Thyroid stimulating hormone receptor (TSHR)
Drug Modality Monoclonal antibody
Indication Graves’ disease
Product Category Biologic
Mechanism of Action TSHR antagonists
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.